Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

Data ReadoutpositivesetmelanotidePositive

AI Analysis

Summary

Rhythm Pharmaceuticals announced publication of Phase 3 TRANSCEND trial results for setmelanotide in acquired hypothalamic obesity in The New England Journal of Medicine.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Phase 3 TRANSCEND trial results published in The New England Journal of Medicine

Importance:7/10

Sentiment:

0.70

Phase 3neuroendocrineobesityMC4R agonistpublication

Related Companies

$RYTM

Read the original article

Published by GlobeNewswire Clinical Studies on July 8, 2026 9:07 PM

Read Original